0000000000073833

AUTHOR

María Isabel Barrio

showing 4 related works from this author

Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

2015

Resumen Pseudomonas aeruginosa es el patogeno mas importante en la infeccion broncopulmonar en fibrosis quistica (FQ). Solo se erradica en la infeccion inicial, mientras que la reduccion de su carga bacteriana es el objetivo terapeutico en la infeccion cronica y exacerbaciones. El cribado neonatal y la farmacocinetica/farmacodinamica han cambiado el manejo del paciente con FQ. Se debe realizar un seguimiento microbiologico en los pacientes sin infeccion por P. aeruginosa. En la infeccion inicial se recomienda tratamiento inhalado (28 dias) con colistina (0,5-2 MU/8 h), tobramicina (300 mg/12 h) o aztreonam (75 mg/8 h) con o sin ciprofloxacino oral (15-20 mg/kg/12 h, 2-3 semanas). En la infe…

Pulmonary and Respiratory MedicineGynecologymedicine.medical_specialtybusiness.industryMedicinebusinessArchivos de Bronconeumología
researchProduct

Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants.

2019

Background Data addressing short- and long-term respiratory morbidity in moderate-late preterm infants are limited. We aim to determine the incidence of recurrent wheezing and associated risk and protective factors in these infants during the first 3 years of life. Methods Prospective, multicenter birth cohort study of infants born at 32+0 to 35+0 weeks' gestation and followed for 3 years to assess the incidence of physician-diagnosed recurrent wheezing. Allergen sensitization and pulmonary function were also studied. We used multivariate mixed-effects models to identify risk factors associated with recurrent wheezing. Results A total of 977 preterm infants were enrolled. Rates of recurrent…

PalivizumabMalePediatricsmedicine.medical_specialtymedicine.medical_treatmentImmunologyPulmonary function testingCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHypersensitivityImmunology and AllergyHumans030212 general & internal medicineAsthmaRespiratory SoundsMechanical ventilationPregnancybusiness.industryIncidence (epidemiology)IncidenceInfant NewbornInfantAtopic dermatitisAllergensmedicine.diseaseAsthmaRespiratory Function Tests030228 respiratory systemChild PreschoolPediatrics Perinatology and Child HealthGestationFemaleImmunizationbusinessInfant Prematuremedicine.drugFollow-Up StudiesPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and ImmunologyREFERENCES
researchProduct

Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study

2017

The first Spanish multi-centre study on the microbiology of cystic fibrosis (CF) was conducted from 2013 to 2014. The study involved 24 CF units from 17 hospitals, and recruited 341 patients. The aim of this study was to characterise Pseudomonas aeruginosa isolates, 79 of which were recovered from 75 (22%) patients. The study determined the population structure, antibiotic susceptibility profile and genetic background of the strains. Fifty-five percent of the isolates were multi-drug-resistant, and 16% were extensively drug-resistant. Defective mutS and mutL genes were observed in mutator isolates (15.2%). Considerable genetic diversity was observed by pulsed-field gel electrophoresis (70 p…

0301 basic medicineMaleCystic FibrosisAntibiotic resistanceArray tubeMulti-locus sequence typing (MLST)medicine.disease_causeGenotypePharmacology (medical)ChildGeneticseducation.field_of_studyMolecular EpidemiologyVirulencePseucforrumus aeruginosaGeneral MedicineMiddle AgedMutS DNA Mismatch-Binding ProteinElectrophoresis Gel Pulsed-FieldInfectious DiseasesChild PreschoolPseudomonas aeruginosaFemalemedicine.drugMicrobiology (medical)AdultAdolescentGenotype030106 microbiologyPopulationVirulenceBiologyCystic fibrosisMicrobiology03 medical and health sciencesYoung AdultAntibiotic resistanceDrug Resistance BacterialmedicineHumansPseudomonas InfectionsTypingeducationGenetic diversityPseudomonas aeruginosaGenetic VariationMutL ProteinsSpainColistinMultilocus Sequence Typing
researchProduct

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

2014

Pseudomonas aeruginosa is the main pathogen in bronchopulmonary infections in cystic fibrosis (CF) patients. It can only be eradicated at early infection stages while reduction of its bacterial load is the therapeutic goal during chronic infection or exacerbations. Neonatal screening and pharmacokinetic/pharmacodynamic knowledge has modified the management of CF-patients. A culture based microbiological follow-up should be performed in patients with no infection with P. aeruginosa. At initial infection, inhaled colistin (0,5-2 MU/tid), tobramycin (300 mg/bid) or aztreonam (75 mg/tid) with or without oral ciprofloxacin (15-20 mg/kg/bid, 2-3 weeks) are recommended. In chronic infections, trea…

medicine.medical_specialtyCystic Fibrosismedicine.drug_classAntibioticsAztreonammedicine.disease_causeCystic fibrosisCystic fibrosischemistry.chemical_compoundInternal medicinemedicineTobramycinHumansPseudomonas InfectionsIntensive care medicinebusiness.industryPseudomonas aeruginosaGeneral Medicinemedicine.diseaseAntibiotic treatmentAnti-Bacterial AgentsCiprofloxacinChronic infectionchemistryChronic DiseasePseudomonas aeruginosaDisease ProgressionColistinbusinessBronchial infectionmedicine.drugArchivos de Bronconeumología (English Edition)
researchProduct